BioNTech takes over U.S. Kite cell therapy manufacturing site

By The Science Advisory Board staff writers

August 4, 2021 -- BioNTech has completed the acquisition of a solid tumor neoantigen T-cell receptor (TCR) R&D platform and clinical manufacturing facility from Kite, a Gilead company, in Gaithersburg, MD.

The acquisition, which follows BioNTech's 2020 acquisition of Neon Therapeutics, expands the company's cell therapy capabilities and manufacturing footprint in North America, according to the firm. The facility will support the development of BioNTech's expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR T-cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms, as well as the newly acquired individualized neoantigen TCR program.

As part of the deal, all Kite employees at the Gaithersburg facility were offered employment with BioNTech. Under the terms of the agreement, Kite will receive a one-time upfront payment from BioNTech to purchase Kite's individualized solid tumor neoantigen TCR discovery platform and the Gaithersburg R&D and clinical manufacturing facility.

Financial terms were not disclosed.

The plant will be fully integrated into BioNTech's U.S. operations.

Kite and Shoreline partner on allogeneic cell therapies
Biopharmaceutical company Kite announced a partnership with Shoreline Biosciences to develop novel cell therapies across a variety of cancer targets.
BioNTech, InstaDeep form AI lab
BioNTech and InstaDeep will form a joint artificial intelligence (AI) lab as part of a multiyear strategic collaboration.

Copyright © 2021

Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
International Society for Pharmaceutical Engineering Annual Meeting
October 30 - November 2
Orlando, Florida United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter